Genus PLC
LSE:GNS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 512
2 354
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Genus PLC
Genus PLC
Cash from Financing Activities
Genus PLC
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genus PLC
LSE:GNS
|
Cash from Financing Activities
-£2.8m
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Financing Activities
$21.1m
|
CAGR 3-Years
149%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Cash from Financing Activities
-£3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Financing Activities
-$883k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Financing Activities
$519.9m
|
CAGR 3-Years
58%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Financing Activities
£34.3m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
221%
|
CAGR 10-Years
N/A
|
|
Genus PLC
Glance View
Amidst the rolling countryside of Britain, Genus PLC has quietly but profoundly reshaped the agricultural landscape since its formation. With roots tracing back to the British government's Milk Marketing Board, Genus blossomed into an influential player at the intersection of biotechnology and farming. This was not by chance, but through a strategic evolution into a global pioneer in animal genetics. At the heart of their operations, Genus enhances animal breeding by leveraging cutting-edge science, particularly the technology of selective breeding and genetics. They focus primarily on two types of livestock: bovine (cattle) and porcine (pigs), catering to agricultural sectors worldwide. Essentially, through their subsidiaries—ABS Global, focusing on cattle, and PIC, specializing in pigs—the company maximizes genetic improvements, aiding farmers in producing leaner, more disease-resistant, and ultimately more productive livestock. The business model of Genus PLC revolves around the intricate science of animal genetics and the commercial viability it crafts from this foundation. By developing genetically superior livestock, they provide a distinct competitive advantage to farmers who seek more yield with less resource input. The company harnesses sophisticated techniques like genomics and advanced biotechnologies, including gene editing, to achieve these outcomes. With each genetic line licensed, Genus receives a license fee, ensuring a steady stream of revenue. Additionally, sales channels are bolstered by continuous consultative partnerships with farmers to enhance productivity, cementing a cycle of value that perpetuates mutual growth. By marrying science with agricultural prosperity, Genus PLC remains a vanguard in a field where innovation is as essential as the soil itself.
See Also
What is Genus PLC's Cash from Financing Activities?
Cash from Financing Activities
-2.8m
GBP
Based on the financial report for Jun 30, 2024, Genus PLC's Cash from Financing Activities amounts to -2.8m GBP.
What is Genus PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
42%
Over the last year, the Cash from Financing Activities growth was 85%. The average annual Cash from Financing Activities growth rates for Genus PLC have been 42% over the past three years .
You don't have any saved screeners yet
